The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Gilead Sciences (GILD) reported a blowout quarter on Tuesday afternoon, topping consensus estimates across the board and possibly stopping the bleeding — at least temporarily — … Continue Reading
Read nowInsights - To say that Biogen (BIIB) disappointed in a big way on Friday would be an understatement. With its second quarter earnings release on Friday morning … Continue Reading
Read nowResearch - Regeneron’s (REGN) Praluent has been approved by the FDA, and the label essentially meets the Base Case scenario that we wrote about yesterday for Esperion … Continue Reading
PremiumResearch - Tomorrow is a big day for developmental cholesterol-lowering medications. The FDA will issue an approval decision for Regeneron (REGN) and Sanofi’s (SNY) PCSK9 inhibitor, Praluent (alirocumab).
Read nowInsights - Second quarter earnings from the large, publicly traded biopharma and specialty pharma companies begin to trickle out on Thursday, July 23. Below is your cheat sheet … Continue Reading
Read nowResearch - As we theorized early this month, Tekmira Pharmaceuticals (TKMR) is changing its name and re prioritizing drug development efforts around Hepatitis B. Unfortunately, our musings that investors may reward the … Continue Reading
Read nowResearch - AFMD is up nearly 200% in less than two months. Taking profit is already a crowding trade on Monday, but we want to be doing … Continue Reading
Premium
